Compare Stocks: ADCT, JBIO, ALMS, and GLUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.47 -13.8%	$1.21	$0.78 ▼ $4.98	$217.04M	1.86	1.90 million shs	1.74 million shs
ALMS Alumis	$6.06 -7.6%	$14.10	$4.37 ▼ $31.35	$849.09M	-0.38	2.61 million shs	2.30 million shs
GLUE Monte Rosa Therapeutics	$9.84 -0.5%	$13.21	$8.94 ▼ $25.77	$843.75M	1.37	1.50 million shs	1.09 million shs
JBIO Jade Biosciences	$13.44 +0.1%	$18.45	$8.36 ▼ $28.00	$853.48M	1.64	1.06 million shs	1.17 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-13.06%	+2.81%	+33.79%	+8.92%	-64.31%
ALMS Alumis	-7.62%	-10.49%	-34.27%	-77.75%	+30.89%
GLUE Monte Rosa Therapeutics	-0.51%	-3.24%	-29.21%	-57.51%	-7.26%
JBIO Jade Biosciences	+0.15%	-2.40%	-26.07%	-34.38%	+46.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.47 -13.8%	$1.21	$0.78 ▼ $4.98	$217.04M	1.86	1.90 million shs	1.74 million shs
ALMS Alumis	$6.06 -7.6%	$14.10	$4.37 ▼ $31.35	$849.09M	-0.38	2.61 million shs	2.30 million shs
GLUE Monte Rosa Therapeutics	$9.84 -0.5%	$13.21	$8.94 ▼ $25.77	$843.75M	1.37	1.50 million shs	1.09 million shs
JBIO Jade Biosciences	$13.44 +0.1%	$18.45	$8.36 ▼ $28.00	$853.48M	1.64	1.06 million shs	1.17 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-13.06%	+2.81%	+33.79%	+8.92%	-64.31%
ALMS Alumis	-7.62%	-10.49%	-34.27%	-77.75%	+30.89%
GLUE Monte Rosa Therapeutics	-0.51%	-3.24%	-29.21%	-57.51%	-7.26%
JBIO Jade Biosciences	+0.15%	-2.40%	-26.07%	-34.38%	+46.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	241.30% Upside
ALMS Alumis	2.86	Moderate Buy	$33.27	449.05% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$26.67	171.00% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	285.04% Upside

Current Analyst Ratings Breakdown

Latest ADCT, JBIO, ALMS, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/11/2026	GLUE Monte Rosa Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$17.00 ➝ $19.00
10/11/2026	GLUE Monte Rosa Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/5/2026	ALMS Alumis	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	GLUE Monte Rosa Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$25.00
10/5/2026	GLUE Monte Rosa Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	ALMS Alumis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
10/1/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$47.00
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
10/1/2026	JBIO Jade Biosciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$55.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	2.30	N/A	N/A	($1.50) per share	-0.98
ALMS Alumis	$24.05M	32.61	N/A	N/A	$2.88 per share	2.10
GLUE Monte Rosa Therapeutics	$123.67M	6.79	N/A	N/A	$3.58 per share	2.75
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-49.11%	-45.62%	N/A

Latest ADCT, JBIO, ALMS, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ALMS Alumis	-$0.73	N/A	N/A	N/A	$1.90 million	N/A
11/10/2026	Q3 2026	ADCT ADC Therapeutics	-$0.21	N/A	N/A	N/A	$18.69 million	N/A
11/5/2026	Q3 2026	GLUE Monte Rosa Therapeutics	-$0.2396	N/A	N/A	N/A	$33.87 million	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
ALMS Alumis	N/A	6.74	6.74
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
JBIO Jade Biosciences	N/A	14.93	14.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ALMS Alumis	N/A
GLUE Monte Rosa Therapeutics	79.96%
JBIO Jade Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ALMS Alumis	33.70%
GLUE Monte Rosa Therapeutics	6.40%
JBIO Jade Biosciences	23.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
JBIO Jade Biosciences	55	63.60 million	48.93 million	N/A

ADCT, JBIO, ALMS, and GLUE Headlines

Recent News About These Companies

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 5% - Should You Buy?

October 7, 2026 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA)

October 2, 2026 | theglobeandmail.com

Analysts Are Bullish on Top Healthcare Stocks: Inogen (INGN), Jade Biosciences (JBIO)

October 2, 2026 | theglobeandmail.com

Jade Biosciences (NASDAQ:JBIO) Stock Keeps Buy Rating at HC Wainwright

October 1, 2026 | marketbeat.com

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow

September 30, 2026 | seekingalpha.com

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

September 30, 2026 | seekingalpha.com

Jade Bioscience Reports Preclinical Data For JADE301

September 30, 2026 | rttnews.com

Transcript : Jade Biosciences, Inc. - Special Call

September 30, 2026 | marketscreener.comM

Jade Biosciences Advances JADE301 Toward Phase 1 Trial In Dermatomyositis

September 30, 2026 | rttnews.com

Jade Biosciences reports JADE301 preclinical data

September 30, 2026 | grafa.comG

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for ...

September 30, 2026 | finance.yahoo.com

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

September 30, 2026 | globenewswire.com

Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of "Moderate Buy" from Analysts

September 25, 2026 | marketbeat.com

Jade Biosciences (NASDAQ:JBIO) Shares Down 9.6% - What's Next?

September 23, 2026 | marketbeat.com

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Jade Biosciences to Participate in Upcoming Conferences

September 1, 2026 | globenewswire.com

Jade Biosciences: Duration Is The Real Product

August 19, 2026 | seekingalpha.com

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | markets.businessinsider.com

Jade Biosciences Inc JBIO

August 2, 2026 | morningstar.comM

Jade Biosciences Stock Short Interest Report | NASDAQ:JBIO | Benzinga

July 20, 2026 | benzinga.com

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

June 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, JBIO, ALMS, and GLUE Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.46 -0.24 (-13.82%)

Closing price 10/14/2026 03:59 PM Eastern

Extended Trading

$1.49 +0.03 (+1.98%)

As of 07:54 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Alumis NASDAQ:ALMS

$6.06 -0.50 (-7.62%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$6.18 +0.13 (+2.06%)

As of 07:51 AM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$9.84 -0.05 (-0.51%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$9.87 +0.03 (+0.26%)

As of 07:47 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Jade Biosciences NASDAQ:JBIO

$13.44 +0.02 (+0.15%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$13.53 +0.09 (+0.69%)

As of 07:48 AM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, JBIO, ALMS, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, JBIO, ALMS, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, JBIO, ALMS, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, JBIO, ALMS, and GLUE Company Descriptions

ADC Therapeutics NYSE:ADCT

Alumis NASDAQ:ALMS

Monte Rosa Therapeutics NASDAQ:GLUE

Jade Biosciences NASDAQ:JBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, JBIO, ALMS, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, JBIO, ALMS, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, JBIO, ALMS, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, JBIO, ALMS, and GLUE Company Descriptions

ADC Therapeutics NYSE:ADCT

Alumis NASDAQ:ALMS

Monte Rosa Therapeutics NASDAQ:GLUE

Jade Biosciences NASDAQ:JBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools